Rolf Larsson
Overview
Explore the profile of Rolf Larsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
3450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Selvin T, Berglund M, Akerstrom A, Zia M, Rudfeldt J, Jarvius M, et al.
SLAS Technol
. 2024 Dec;
29(6):100232.
PMID: 39638255
To facilitate the translation of immunotherapies from bench to bedside, predictive preclinical models are essential. We developed the in vivo immuno-oncology Hollow Fiber Assay (HFA) to bridge the gap between...
2.
Selvin T, Berglund M, Lenhammar L, Lindskog M, Jarvius M, Larsson R, et al.
BMC Pharmacol Toxicol
. 2024 Mar;
25(1):25.
PMID: 38444002
Background: It has become evident in the field of oncology that the outcome of medical treatment is influenced by the combined effect exerted on both cancer- and immune cells. Therefore,...
3.
Cashin P, Soderstrom M, Blom K, Artursson S, Andersson C, Larsson R, et al.
Br J Surg
. 2023 Mar;
110(9):1080-1083.
PMID: 36918737
No abstract available.
4.
Selvin T, Berglund M, Lenhammar L, Jarvius M, Nygren P, Fryknas M, et al.
BMC Cancer
. 2023 Feb;
23(1):164.
PMID: 36803614
Background: High-throughput screening (HTS) of small molecule drug libraries has greatly facilitated the discovery of new cancer drugs. However, most phenotypic screening platforms used in the field of oncology are...
5.
Bjersand K, Blom K, Poromaa I, Stalberg K, Lejon A, Backman F, et al.
Int J Oncol
. 2022 Sep;
61(4).
PMID: 36082820
Epithelial ovarian cancer (EOC) is divided into type I and type II based on histopathological features. Type I is clinically more indolent, but also less sensitive to chemotherapy, compared with...
6.
Andersson C, Ye J, Blom K, Fryknas M, Larsson R, Nygren P
Anticancer Drugs
. 2022 Sep;
34(1):92-102.
PMID: 36066384
Cancer patients often suffer from cancer symptoms, treatment complications and concomitant diseases and are, therefore, often treated with several drugs in addition to anticancer drugs. Whether such drugs, here denoted...
7.
Selvin T, Fasterius E, Jarvius M, Fryknas M, Larsson R, Andersson C
Sci Rep
. 2022 Jul;
12(1):11960.
PMID: 35831404
Understanding the immunological effects of chemotherapy is of great importance, especially now that we have entered an era where ever-increasing pre-clinical and clinical efforts are put into combining chemotherapy and...
8.
Ek F, Blom K, Selvin T, Rudfeldt J, Andersson C, Senkowski W, et al.
Sci Rep
. 2022 May;
12(1):8943.
PMID: 35624293
Quiescent cancer cells in malignant tumors can withstand cell-cycle active treatment and cause cancer spread and recurrence. Three-dimensional (3D) cancer cell models have led to the identification of oxidative phosphorylation...
9.
Lu X, Maturi N, Jarvius M, Yildirim I, Dang Y, Zhao L, et al.
Nat Commun
. 2022 Apr;
13(1):2236.
PMID: 35469026
There is ample support for developmental regulation of glioblastoma stem cells. To examine how cell lineage controls glioblastoma stem cell function, we present a cross-species epigenome analysis of mouse and...
10.
Karlsson H, Fryknas M, Senkowski W, Larsson R, Nygren P
Oncol Lett
. 2022 Mar;
23(4):123.
PMID: 35261637
Nitazoxanide is a Food and Drug Administration-approved antiprotozoal drug recently demonstrated to be selectively active against quiescent and glucose-deprived tumour cells. This drug also has several characteristics that suggest its...